Screener
AbCellera Biologics Inc. ABCL Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
| Line item | December 31, 2025 | June 30, 2026 |
|---|---|---|
| Total current liabilities | 64,307 | 53,189 |
| Long-term liabilities: | ||
| Operating lease liability | 137,403 | 129,948 |
| Deferred revenue | 3,500 | 40,450 |
| Deferred government contributions | 174,453 | 178,254 |
| Other long-term liabilities | 10,383 | 9,714 |
| Total long-term liabilities | 325,739 | 358,366 |
| Total liabilities | 390,046 | 411,555 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is AbCellera Biologics Inc.'s contract liabilities?
- AbCellera Biologics Inc. (ABCL) reported contract liabilities of $40.45M in Q2 2026.
- How has AbCellera Biologics Inc.'s contract liabilities changed year-over-year?
- AbCellera Biologics Inc.'s contract liabilities increased by 247.7% year-over-year, from $11.63M to $40.45M.
- What is the long-term trend for AbCellera Biologics Inc.'s contract liabilities?
- Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s contract liabilities has grown at a -40.2% compound annual growth rate (CAGR), from $27.41M to $3.5M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.
Ask your AI about AbCellera Biologics Inc.'s contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude